drugset / Trial / NCT00182052

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

NCT00182052

RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.

Timeline

Start
2000-09
Primary completion
2003-08
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosiglitazone Small molecule Oral